Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
Cappagli V, Moriconi D, Bonadio AG, Giannese D, La Manna G, Egidi MF, Comai G, Vischini G, Bottici V, Elisei R, Viola D.
Cappagli V, et al. Among authors: giannese d.
J Endocrinol Invest. 2021 Jan;44(1):95-103. doi: 10.1007/s40618-020-01272-y. Epub 2020 May 3.
J Endocrinol Invest. 2021.
PMID: 32363491